TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
Head-To-Head Comparison: Karyopharm Therapeutics (NASDAQ:KPTI) & TransCode Therapeutics (NASDAQ:RNAZ)
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
TransCode Therapeutics (NASDAQ:RNAZ) Shares Up 0.9% – Here’s Why
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
TransCode Therapeutics, Inc. Announces Closing of Public Offering
Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by Analyst
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
TransCode Therapeutics Open Letter to Shareholders
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic